<DOC>
	<DOCNO>NCT01160731</DOCNO>
	<brief_summary>RATIONALE : Panobinostat may stop growth tumor cell block enzymes need cell growth block blood flow tumor . Drugs use chemotherapy , etoposide cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Giving panobinostat together etoposide cisplatin may kill tumor cell . PURPOSE : This phase I trial study side effect best dose panobinostat give together etoposide cisplatin first-line therapy treat patient extensive-stage small cell lung cancer .</brief_summary>
	<brief_title>Panobinostat , Etoposide , Cisplatin First-Line Therapy Treating Patients With Extensive-Stage Small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine maximum-tolerated dose , recommend dose , activity panobinostat give combination etoposide cisplatin patient extensive-stage small cell lung cancer . Secondary - To estimate time-to-progression , duration response , disease stabilization patient . - To estimate overall survival patient . - To determine pharmacokinetic profile panobinostat combination etoposide cisplatin . - To assess overall safety profile panobinostat patient . - To determine adverse event patient treat regimen . - To assess quality life patient . OUTLINE : This multicenter , dose-escalation study panobinostat . Patients receive chemotherapy comprise cisplatin IV day 1 , etoposide IV day 1-3 , panobinostat IV 30 minute day 1 8 . Treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . Quality life assess baseline periodically study treatment follow , use questionnaire EQ-5D ( Euro QoL ) . Blood sample may collect baseline periodically study treatment pharmacokinetic assessment biomarker translational study . After completion study treatment , patient follow 4 week every 3 month .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Small Cell Lung Carcinoma</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Panobinostat</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm small cell lung cancer Extensivestage disease Measurable disease accord RECIST criterion No symptomatic brain metastasis meningeal tumor PATIENT CHARACTERISTICS : ECOG performance status 01 Life expectancy ≥ 6 month Absolute neutrophil count &gt; 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hemoglobin ≥ 10.0 g/dL Serum creatinine ≤ 1.5 x upper limit normal ( ULN ) OR 24hour creatinine clearance ≥ 60 mL/min Magnesium , potassium , phosphorus ≥ low limit normal OR correctable supplement prior study treatment AST/ALT ≤ 2.5 x ULN ( ≤ 5.0 x ULN hepatic metastasis present ) Serum bilirubin ≤ 1.5 x ULN Alkaline phosphatase ≤ 2.5 x ULN OR liver fraction ≤ 2.5 x ULN Not pregnant nursing Negative pregnancy test Fertile patient must use effective double contraception ( least 1 barrier method ) least 30 day completion study treatment No impaired cardiac function , include one following : LVEF &lt; 45 % determined ECHO Complete leave bundle branch block , obligate use cardiac pacemaker , congenital long QT syndrome , history presence atrial ventricular tachyarrhythmias , clinically significant rest bradycardia ( &lt; 50 beat per minute ) , QTcF &gt; 480 msec screen ECG , right bundle branch block leave anterior hemiblock ( bifascicular block ) Uncontrolled angina pectoris acute myocardial infarction within past 3 month Other clinically significant heart disease ( e.g. , congestive heart failure , uncontrolled hypertension , history labile hypertension , history poor compliance antihypertensive regimen ) No history HIV AIDSrelated illness No acute chronic liver renal disease No concurrent severe and/or uncontrolled medical condition could cause unacceptable safety risk compromise compliance protocol , include follow : Uncontrolled diabetes Chronic obstructive chronic restrictive pulmonary disease Active uncontrolled infection No know immediate delay hypersensitivity reaction idiosyncrasy drug chemically relate panobinostat , cisplatin , etoposide No hearing impairment would contraindication use cisplatin PRIOR CONCURRENT THERAPY : No prior chemotherapy No investigational drug experimental medication treatment within past 30 day 5 halflives , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>extensive stage small cell lung cancer</keyword>
</DOC>